Research Progress and Combination Application Strategies of Immune Checkpoint Antibodies in Tumor Immunotherapy

Mechanisms of Action and Major Targets of Immune Checkpoint Antibodies

Immune checkpoint antibodies are biologic agents that reactivate antitumor immune responses by blocking inhibitory receptors on the surface of T cells (such as PD-1 and CTLA-4) or their ligands (such as PD-L1). The PD-1/PD-L1 pathway is often exploited in the tumor microenvironment to suppress effector T cell function, whereas CTLA-4 primarily regulates the early activation phase of T cells. Monoclonal antibodies targeting these checkpoints have demonstrated clinical benefit in multiple solid tumors. Common formulations include intravenous infusion preparations, and dosing intervals vary according to drug half-life and clinical trial protocols.

Clinical Research Progress and Expansion of Indications

In recent years, immune checkpoint antibodies have accumulated substantial clinical data in non-small cell lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma. Researchers have also explored their use in gastrointestinal tumors such as gastric cancer, liver cancer, and esophageal cancer, with some already receiving regulatory approval. Notably, response rates to immune checkpoint antibodies differ across tumor types, which may be related to factors such as tumor mutational burden and the degree of immune cell infiltration in the microenvironment.

Combination Treatment Strategies: Synergistic Efficacy and Safety Management

The efficacy of single-agent immune checkpoint antibody therapy is limited, making combination therapy an important direction. Common combination regimens include: PD-1 antibodies combined with CTLA-4 antibodies, immune checkpoint antibodies combined with chemotherapy, combined with anti-angiogenic drugs, and combined with radiotherapy. Combination therapy requires attention to the increased risk of immune-related adverse events (irAEs), such as colitis, pneumonitis, and thyroid dysfunction. Clinical use must follow standardized guidelines and involve individualized patient assessment.

Challenges and Future Prospects

Primary and acquired resistance are major obstacles in immune checkpoint antibody therapy. In current research, biomarkers such as PD-L1 expression levels and mismatch repair status are used for patient selection, but the problem of precise stratification has not yet been fully resolved. In addition, antibody drugs targeting novel immune checkpoints such as LAG-3, TIGIT, and TIM-3 are in clinical trials and may provide more options for combination therapy. With advances in antibody engineering technology, bispecific antibodies and Fc-engineered modifications also show potential for optimizing efficacy and reducing toxicity.

Conclusion

Immune checkpoint antibodies have become an important cornerstone of tumor immunotherapy. Through deeper understanding of their mechanisms of action, rational design of combination regimens, and strengthened biomarker research, it is expected that patient benefit can be further improved. Researchers and clinicians need to continuously monitor developments in this field to advance the practice of precision immunotherapy.